相关实验视频
Updated: Jun 24, 2025
12:38
Screening Peptides that Activate MRGPRX2 using Engineered HEK Cells
Published on: November 6, 2021
2.5K
对MR3331717的作用机制的研究
Joachim Neumann1, C Hesse2, S Yahiaoui3
1Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Magdeburger Straße 4, 06097, Halle (Saale), Germany. joachim.neumann@medizin.uni-halle.de.
Naunyn-Schmiedeberg's archives of pharmacology
|June 10, 2024
概括
MR33317作为心脏中的5-HT4受体激动剂,可能治疗阿尔茨海默病. 然而,这种作用可能会增加心房的风险.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
- 神经科学是一个神经科学.
背景情况:
- MR33317是一种乙胆酶抑制剂和大脑5-HT4受体激动剂,具有潜在的阿尔茨海默病治疗应用.
- 它的治疗效果可能来自于双重协同作用.
- 这项研究研究了MR33317在心脏5-HT4受体上的活性.
研究的目的:
- 为了确定MR33317是否刺激心脏中的5-HT4受体.
- 为了评估MR33317对心脏收缩性和心率的功能影响.
- 评估MR33317对心脏活动的潜在临床影响.
主要方法:
- 测试MR33317在与心脏5-HT4受体过度表达的和没有心脏5-HT4受体过度表达的孤立小鼠心房制剂上.
- 评估MR33317对人心收缩力和心跳速率的影响,在人心室制剂中,有或没有西洛斯塔米德.
- 研究热和GR125487对MR33317诱导的人类心房收缩性变化的影响.
主要成果:
- 在过度表达5-HT4受体的小鼠中,MR33317增加了心房收缩和跳动率,但不是在野生型小鼠中.
- 在人类心房中,MR33317仅在与西洛斯塔米德 (一种PDE III抑制剂) 结合时,才能增加收缩力.
- 在人类心房中,这种效应被热热和GR125487抑制,证实MR33317是5-HT4受体激动剂.
结论:
- MR33317作为人类心脏5-HT4受体的激动剂.
- 药物的心脏作用,特别是与固酶III抑制一起,表明在临床使用中有可能诱导心房动.
相关概念视频
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.8K
01:24Cholinergic Antagonists: Pharmacokinetics
432
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
432
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
1.8K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.8K
01:25Adrenergic Agonists: Indirect-Acting Agents
1.6K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.6K
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.3K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.3K
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
554
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
554